Warren Fiskus

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (12)

Behnam Nabet

Assistant Professor

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Michael Green

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jan A. Burger

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Koichi Takahashi

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Farhad Ravandi

Professor of Medicine, Chief Section of AML

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Kapil Bhalla

UNITED STATES

View details

PRITHVIRAJ BOSE

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Patrick Reville

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Elias J. Jabbour

UNITED STATES

View details

Courtney D. DiNardo

UNITED STATES

View details

Mike Collins

Foghorn Therapeutics (United States)

UNITED STATES

View details

Steffen Boettcher

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Warren Fiskus

Research Interests

Explore related searches

Contact this professor

Articles (13)

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Collaborators (12)

Behnam Nabet

Michael Green

Jan A. Burger

Koichi Takahashi

Farhad Ravandi

Kapil Bhalla

PRITHVIRAJ BOSE

Patrick Reville

Elias J. Jabbour

Courtney D. DiNardo

Mike Collins

Steffen Boettcher

Make your next move.